TMC310911 (Standard)
TMC310911 (Standard) (ASC-09 (Standard)) is the analytical standard of TMC310911 (HY-107123). This product is intended for research and analytical applications. TMC310911 is a potent and orally active HIV type-1 (HIV-1) protease inhibitor with EC50 values ranged from 2.2 nM to 14.2 nM for wild-type HIV-1. TMC310911 has potent activity against a wide spectrum of recombinant HIV-1 isolates. TMC310911 has strong antiviral activity.
For research use only. We do not sell to patients.
- CAS No.: 1000287-05-7
- Formula: C38H53N5O7S2
- Molecular Weight:755.99
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
-
HY-N2565
RosamultinHIV-1 Protease Inhibitor -
HY-N10420
HinokininHIV-1 Inhibitor -
HY-N2006
Ganoderic acid BHIV Protease Inhibitor -
HY-N0554
Escin IALOXL2 Inhibitor, EMT Inhibitor -
HY-107123
TMC310911HIV-1 Protease Inhibitor -
HY-N0556
Isoescin IAHIV Protease Inhibitor -
HY-N2006R
Ganoderic acid B (Standard)HIV Protease Inhibitor -
HY-N0556R
Isoescin IA (Standard)HIV Protease Inhibitor -
HY-N10420R
Hinokinin (Standard)HIV-1 Inhibitor -
HY-N0554R
Escin IA (Standard)HIV-1 Protease Inhibitor
Biological Activity
Description
IC50 & Target
EC50: 2.2-14.2 nM (Wild-type HIV-1)[1]
Chemical Information
-
CAS No. 1000287-05-7
-
Molecular Weight 755.99
-
Formula C38H53N5O7S2
-
SMILES
O=C(O[C@@H]1[C@@]2([H])[C@@](OCC2)([H])OC1)N[C@@H](CC3=CC=CC=C3)[C@H](O)CN(S(=O)(C4=CC=C5N=C(NC6CCN(C7CCCC7)CC6)SC5=C4)=O)CC(C)C
-
Synonyms
ASC-09 (Standard)
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
Purity & Documentation
References
[1]. Dierynck I, et al. TMC310911, a novel human immunodeficiency virus type 1 protease inhibitor, shows in vitro an improved resistance profile and higher genetic barrier to resistance compared with current protease inhibitors. Antimicrob Agents Chemother. 2011 Dec;55(12):5723-31. [Content Brief]
[2]. Stellbrink HJ, et al. Antiviral activity, pharmacokinetics, and safety of the HIV-1 protease inhibitor TMC310911, coadministered with ritonavir, in treatment-naive HIV-1-infected patients. J Acquir Immune Defic Syndr. 2014 Mar 1;65(3):283-9. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
TMC310911 (Standard) Related Classifications
HY-107123R Related Classifications
Powered by Bioz